<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00436475</url>
  </required_header>
  <id_info>
    <org_study_id>DK76092 (completed)</org_study_id>
    <secondary_id>R01DK076092</secondary_id>
    <secondary_id>DK76092</secondary_id>
    <nct_id>NCT00436475</nct_id>
  </id_info>
  <brief_title>Vitamin D and Calcium Homeostasis for Prevention of Type 2 Diabetes</brief_title>
  <acronym>CaDDM</acronym>
  <official_title>Vitamin D and Calcium Homeostasis for Prevention of Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tufts Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Tufts Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the randomized trial is to quantify the effect of vitamin D and calcium
      supplementation on beta-cell function, insulin sensitivity, glucose tolerance and systemic
      inflammation and other cardiometabolic outcomes in ambulatory adults at high risk for type 2
      diabetes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There is animal and human observational evidence to suggest that vitamin D and calcium are
      important in modifying t2DM risk but there are critical gaps in our knowledge about the
      clinical magnitude of the association with t2DM and potential mechanisms in humans. We are
      conducting a randomized trial to quantify the effect of vitamin D and calcium supplementation
      on beta-cell function, insulin sensitivity, glucose tolerance and systemic inflammation and
      other cardiometabolic outcomes in ambulatory adults at high risk for t2DM. We anticipate that
      the research proposed in this application is significant because it will provide the basis
      for defining feasible nutritional interventions that promotes prevention of t2DM. Based on
      the results of the proposed studies and future work in this area, vitamin D and calcium
      supplementation can assume an important role in the treatment of t2DM and in the prevention
      of the disease in the 41 million Americans who are at risk of developing t2DM.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2007</start_date>
  <completion_date type="Actual">November 2009</completion_date>
  <primary_completion_date type="Actual">November 2009</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Chang in Disposition Index, a Measure of Beta Cell Function</measure>
    <time_frame>baseline and 4 months</time_frame>
    <description>Range is 0 to infinity Lower is better.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Hemoglobin A1c</measure>
    <time_frame>Baseline to 4 months</time_frame>
    <description>This outcome measures change in Hemoglobin A1c, a measure of glycemia</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">92</enrollment>
  <condition>Glucose Intolerance</condition>
  <condition>Type 2 Diabetes Mellitus</condition>
  <condition>Metabolic Syndrome</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Vitamin D3 2,000 IU daily plus Calcium Carbonate 400 mg twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Vitamin D3 2,000 IU daily plus Calcium-Placebo twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Vitamin D3-Placebo plus Calcium Carbonate 400 mg twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Vitamin D3-Placebo plus Calcium-Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamin D3 2,000 IU orally once daily</intervention_name>
    <description>Vitamin D3 2,000 IU orally once daily</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Calcium Carbonate 400 mg orally twice daily</intervention_name>
    <description>Calcium Carbonate 400 mg orally twice daily</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamin D3-Placebo</intervention_name>
    <description>Vitamin D3-Placebo</description>
    <arm_group_label>3</arm_group_label>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Calcium-Placebo</intervention_name>
    <description>Calcium-Placebo</description>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ethnicity: all ethnic groups

          -  Gender: men and women

          -  Age

               1. Lower age limit: 40 years inclusive

               2. Upper age limit: NONE

          -  BMI

               1. Lower BMI limit: 25 inclusive

               2. Upper BMI limit: 40 inclusive

          -  Glucose Intolerance / Mild Diabetes defined as

               1. Fasting glucose ≥100 mg/dl OR

               2. 2-hr glucose after OGTT ≥140 mg/dl OR

               3. 5.8 ≤ Hemoglobin A1c ≤ 7

        Major Exclusion Criteria:

          -  Diabetes requiring pharmacotherapy

          -  Smoking

          -  Hyperparathyroidism

          -  Hypercalcemia (Calcium &gt; 10.5 mg/dl)

          -  Kidney stone

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anastassios G Pittas, MD MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tufts Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tufts-New England Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.caddm.org</url>
    <description>Related Info</description>
  </link>
  <reference>
    <citation>Pittas AG, Lau J, Hu FB, Dawson-Hughes B. The role of vitamin D and calcium in type 2 diabetes. A systematic review and meta-analysis. J Clin Endocrinol Metab. 2007 Jun;92(6):2017-29. Epub 2007 Mar 27. Review.</citation>
    <PMID>17389701</PMID>
  </reference>
  <reference>
    <citation>Pittas AG, Harris SS, Stark PC, Dawson-Hughes B. The effects of calcium and vitamin D supplementation on blood glucose and markers of inflammation in nondiabetic adults. Diabetes Care. 2007 Apr;30(4):980-6. Epub 2007 Feb 2.</citation>
    <PMID>17277040</PMID>
  </reference>
  <reference>
    <citation>Pittas AG, Dawson-Hughes B, Li T, Van Dam RM, Willett WC, Manson JE, Hu FB. Vitamin D and calcium intake in relation to type 2 diabetes in women. Diabetes Care. 2006 Mar;29(3):650-6.</citation>
    <PMID>16505521</PMID>
  </reference>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>February 16, 2007</study_first_submitted>
  <study_first_submitted_qc>February 16, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 19, 2007</study_first_posted>
  <results_first_submitted>September 26, 2016</results_first_submitted>
  <results_first_submitted_qc>July 8, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">July 30, 2019</results_first_posted>
  <last_update_submitted>July 8, 2019</last_update_submitted>
  <last_update_submitted_qc>July 8, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Glucose intolerance</keyword>
  <keyword>Type 2 diabetes mellitus</keyword>
  <keyword>Metabolic syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Metabolic Syndrome</mesh_term>
    <mesh_term>Glucose Intolerance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcium, Dietary</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Calcium Carbonate</mesh_term>
    <mesh_term>Calcium</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Vitamin D-Calcium</title>
          <description>Vitamin D3 2,000 IU daily plus Calcium Carbonate 400 mg twice daily</description>
        </group>
        <group group_id="P2">
          <title>Vitamin D Only</title>
          <description>Vitamin D3 2,000 IU daily plus Calcium-Placebo twice daily</description>
        </group>
        <group group_id="P3">
          <title>Calcium Only</title>
          <description>Vitamin D3-Placebo plus Calcium Carbonate 400 mg twice daily</description>
        </group>
        <group group_id="P4">
          <title>Placebo-Placebo</title>
          <description>Vitamin D3-Placebo plus Calcium-Placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="23"/>
                <participants group_id="P3" count="22"/>
                <participants group_id="P4" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="22"/>
                <participants group_id="P3" count="21"/>
                <participants group_id="P4" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Vitamin D-Calcium</title>
          <description>Vitamin D3 2,000 IU daily plus Calcium Carbonate 400 mg twice daily</description>
        </group>
        <group group_id="B2">
          <title>Vitamin D Only</title>
          <description>Vitamin D3 2,000 IU daily plus Calcium-Placebo twice daily</description>
        </group>
        <group group_id="B3">
          <title>Calcium Only</title>
          <description>Vitamin D3-Placebo plus Calcium Carbonate 400 mg twice daily</description>
        </group>
        <group group_id="B4">
          <title>Placebo-Placebo</title>
          <description>Vitamin D3-Placebo plus Calcium-Placebo</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="23"/>
            <count group_id="B2" value="23"/>
            <count group_id="B3" value="22"/>
            <count group_id="B4" value="24"/>
            <count group_id="B5" value="92"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="22"/>
                    <measurement group_id="B4" value="24"/>
                    <measurement group_id="B5" value="92"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57" spread="2"/>
                    <measurement group_id="B2" value="57" spread="2"/>
                    <measurement group_id="B3" value="57" spread="2"/>
                    <measurement group_id="B4" value="59" spread="2"/>
                    <measurement group_id="B5" value="57" spread="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="13"/>
                    <measurement group_id="B5" value="47"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="22"/>
                    <measurement group_id="B4" value="24"/>
                    <measurement group_id="B5" value="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Chang in Disposition Index, a Measure of Beta Cell Function</title>
        <description>Range is 0 to infinity Lower is better.</description>
        <time_frame>baseline and 4 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vitamin D-Calcium</title>
            <description>Vitamin D3 2,000 IU daily plus Calcium Carbonate 400 mg twice daily</description>
          </group>
          <group group_id="O2">
            <title>Vitamin D Only</title>
            <description>Vitamin D3 2,000 IU daily plus Calcium-Placebo twice daily</description>
          </group>
          <group group_id="O3">
            <title>Calcium Only</title>
            <description>Vitamin D3-Placebo plus Calcium Carbonate 400 mg twice daily</description>
          </group>
          <group group_id="O4">
            <title>Placebo-Placebo</title>
            <description>Vitamin D3-Placebo plus Calcium-Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Chang in Disposition Index, a Measure of Beta Cell Function</title>
          <description>Range is 0 to infinity Lower is better.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="287" spread="170"/>
                    <measurement group_id="O2" value="314" spread="183"/>
                    <measurement group_id="O3" value="-122" spread="177"/>
                    <measurement group_id="O4" value="-129" spread="174"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Hemoglobin A1c</title>
        <description>This outcome measures change in Hemoglobin A1c, a measure of glycemia</description>
        <time_frame>Baseline to 4 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vitamin D-Calcium</title>
            <description>Vitamin D3 2,000 IU daily plus Calcium Carbonate 400 mg twice daily</description>
          </group>
          <group group_id="O2">
            <title>Vitamin D Only</title>
            <description>Vitamin D3 2,000 IU daily plus Calcium-Placebo twice daily</description>
          </group>
          <group group_id="O3">
            <title>Calcium Only</title>
            <description>Vitamin D3-Placebo plus Calcium Carbonate 400 mg twice daily</description>
          </group>
          <group group_id="O4">
            <title>Placebo-Placebo</title>
            <description>Vitamin D3-Placebo plus Calcium-Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Hemoglobin A1c</title>
          <description>This outcome measures change in Hemoglobin A1c, a measure of glycemia</description>
          <units>% of hemoglobin</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="22"/>
                <count group_id="O4" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.05" spread="0.05"/>
                    <measurement group_id="O2" value="0.08" spread="0.05"/>
                    <measurement group_id="O3" value="0.09" spread="0.05"/>
                    <measurement group_id="O4" value="0.18" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Vitamin D-Calcium</title>
          <description>Vitamin D3 2,000 IU daily plus Calcium Carbonate 400 mg twice daily</description>
        </group>
        <group group_id="E2">
          <title>Vitamin D Only</title>
          <description>Vitamin D3 2,000 IU daily plus Calcium-Placebo twice daily</description>
        </group>
        <group group_id="E3">
          <title>Calcium Only</title>
          <description>Vitamin D3-Placebo plus Calcium Carbonate 400 mg twice daily</description>
        </group>
        <group group_id="E4">
          <title>Placebo-Placebo</title>
          <description>Vitamin D3-Placebo plus Calcium-Placebo</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Hospitalization</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye irritation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Joint pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>UTI</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>URI</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Fewer participants than anticipated were enrolled because of reduction in budget.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Anastassios G. Pittas</name_or_title>
      <organization>Tufts Medical Center</organization>
      <phone>617-636-5689</phone>
      <email>apittas@tuftsmedicalcenter.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

